A multi-modal comparison chart illustrating the progression of Non-alcoholic Fatty Liver Disease (NAFLD) across four stages: Normal liver, Simple steatosis, Non-alcoholic steatohepatitis (NASH), and Fibrosis. The top row shows gross anatomical illustrations where the liver transitions from a healthy reddish-brown to a pale yellowish-orange (steatosis/NASH) and finally a mottled purplish-brown (fibrosis). The middle row presents histological micrographs (H&E and Masson's Trichrome staining), highlighting the emergence of clear macrovesicular fat droplets in steatosis, inflammatory infiltration in NASH, and blue-stained collagen deposition in the fibrosis stage. The bottom row displays B-mode ultrasound images with Tissue Attenuation Imaging (TAI) overlays. As the disease severity increases from healthy to severe steatosis, the liver parenchyma exhibits increased echogenicity (brightness) and the quantitative TAI value rises sequentially from 0.62 to 1.21 dB/cm/MHz. This infographic serves as an educational tool for medical professionals to correlate gross morphology, cellular pathology, and diagnostic ultrasound parameters in hepatology.

Summary : This flowchart presents an overview of the management algorithm for Nonalcoholic Fatty Liver Disease (NAFLD), highlighting high-risk groups, diagnostic steps, risk stratification, and management priorities. flowchart: # High-Risk Groups : • Prediabetes or T2D (rectangle) • Obesity¹ or ≥2 cardiometabolic risk factors² (rectangle) • Hepatic steatosis (on imaging) or ↑ AST or ALT (>30 IU/L) (rectangle) # Diagnostic Steps : • History and physical exam (arrow from high-risk groups to NAFLD) • Rule out 2° causes³ (rectangle, arrow from hepatic steatosis to this node) # Central Node : • NAFLD (liver illustration, central node) # Management Pathways : • Prevention of Cardiovascular Disease (rectangle, arrow from NAFLD) • Prevention of Cirrhosis (rectangle, arrow from NAFLD) • Management of: 1. Obesity 2. Diabetes 3. Hypertension 4. Atherogenic dyslipidemia (list, right side) # Fibrosis Risk Stratification : • Fibrosis Risk Stratification (rectangle, arrow from NAFLD) • Low Risk (green rectangle, arrow from stratification) • Indeterminate Risk (yellow rectangle, arrow from stratification) • High Risk (red rectangle, arrow from stratification) # Connectors : • Arrows connect high-risk groups to NAFLD via history/physical exam and diagnostic steps. • Arrows from NAFLD to prevention and management nodes. • Arrows from NAFLD to fibrosis risk stratification, then to risk categories. # Layout : • Left column: high-risk groups and diagnostic steps. • Center: NAFLD as the main node. • Right: management priorities and prevention. • Bottom: fibrosis risk stratification and risk categories. # Footnotes : • ¹ Adiposity-based chronic disease (ABCD) definition. • ² Cardiometabolic risk factors: waist circumference, triglycerides, HDL-C, BP, fasting glucose. • ³ Secondary causes: alcohol, hepatitis B/C, Wilson’s disease, etc. Analysis : • The algorithm emphasizes identifying high-risk individuals, confirming NAFLD, ruling out secondary causes, and stratifying fibrosis risk to guide management. • Management focuses on preventing cardiovascular disease and cirrhosis, and controlling obesity, diabetes, hypertension, and dyslipidemia. • The flowchart is linear with branching for risk stratification, supporting a stepwise clinical approach.

Summary : This flowchart presents the management algorithm for Nonalcoholic Fatty Liver Disease (NAFLD), highlighting risk groups, diagnostic steps, and management priorities. flowchart: # High-Risk Groups for NAFLD : • Prediabetes or Type 2 Diabetes (T2D) (rectangle) • Obesity (adiposity-based chronic disease) and/or ≥2 cardiometabolic risk factors (rectangle) • Hepatic steatosis (on imaging) or elevated AST or ALT (>30 IU/L) (rectangle) # Initial Assessment : • History and physical exam (rectangle) • Rule out secondary causes (rectangle) # Central Node : • NAFLD (liver illustration, central node) # Management Pathways : • Prevention of Cardiovascular Disease (rectangle, heart illustration) • Prevention of Cirrhosis (rectangle, cirrhotic liver illustration) • Management of: 1. Obesity 2. Diabetes 3. Hypertension 4. Atherogenic dyslipidemia (yellow box) # Fibrosis Risk Stratification : • Low Risk (green box) • Indeterminate Risk (yellow box) • High Risk (red box) # Connectors : • Arrows from high-risk group boxes to NAFLD central node. • Arrows from NAFLD to history/physical exam, rule out secondary causes, prevention of cardiovascular disease, prevention of cirrhosis, and management box. • Arrow from NAFLD to fibrosis risk stratification, which branches into low, indeterminate, and high risk. # Layout : • Flow is left-to-right and top-to-bottom, starting with risk groups, moving to NAFLD diagnosis, then branching to management and risk stratification. • Visual illustrations (liver, heart, cirrhotic liver) enhance key nodes. # Abbreviations & Footnotes : • ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; T2D: Type 2 diabetes mellitus. • Footnotes clarify definitions for obesity, cardiometabolic risk factors, and secondary causes of liver enzyme elevation. # Analysis : • The algorithm emphasizes early identification of high-risk individuals, exclusion of secondary causes, and stratification by fibrosis risk. • Management focuses on metabolic comorbidities and prevention of cardiovascular and liver-related complications. • The flowchart visually organizes the stepwise approach to NAFLD care, integrating risk assessment and targeted interventions.

A pathophysiology diagram illustrating the progression of Non-Alcoholic Fatty Liver Disease (NAFLD) and the protective mechanisms of dietary carotenoids. The flow depicts the transition from a 'Normal Liver' to 'Steatosis' (characterized by triglyceride, fatty acid, and cholesterol accumulation), then to 'NASH' (Non-Alcoholic Steatohepatitis, marked by lipid peroxidation, activated Kupffer cells, and hepatic stellate cells), and finally to 'Cirrhosis' with advanced fibrosis. The diagram maps the systemic influence of obesity and adipose tissue, which contribute to increased insulin, glucose, free fatty acids (FFAs), and cytokines. Specific carotenoids are shown as therapeutic modulators: Lycopene (LYC) promotes beta-oxidation and inhibits inflammation; beta-carotene (beta-CAR) inhibits insulin resistance and the transition to cirrhosis; and Lutein (LUT), Zeaxanthin (ZEA), and beta-cryptoxanthin (beta-CRIPX) act as inhibitors of disease progression pathways between steatosis and NASH. Green arrows indicate promotion/increase, while red T-bars indicate inhibition or blocking of pathological pathways, emphasizing the antioxidant and anti-inflammatory roles of these nutrients in preventing hepatocyte damage and fibrosis.